Parallel Advisors’s Pacira BioSciences PCRX Stock Holding History

Parallel Advisors’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.52K	Hold	178	–	–	﹤0.01%	3254
2026 Q1	$4.02K	Buy	178 +29	+19%	+$644	﹤0.01%	3118
2025 Q4	$3.86K	Hold	149	–	–	﹤0.01%	2932
2025 Q3	$3.84K	Hold	149	–	–	﹤0.01%	2880
2025 Q2	$3.56K	Hold	149	–	–	﹤0.01%	2861
2025 Q1	$3.7K	Hold	149	–	–	﹤0.01%	2784
2024 Q4	$2.81K	Buy	149 +122	+452%	+$2.14K	﹤0.01%	2848
2024 Q3	$406	Buy	+27	New	+$462	﹤0.01%	3213
2024 Q2	–	Sell	-223	Closed	-$6.52K	–	3398
2024 Q1	$6.52K	Sell	223 -57	-20%	-$1.75K	﹤0.01%	2448
2023 Q4	$9.45K	Buy	280 +220	+367%	+$6.44K	﹤0.01%	2315
2023 Q3	$1.84K	Buy	60 +58	+2,900%	+$2.09K	﹤0.01%	2850
2023 Q2	$80	Sell	2 -31	-94%	-$1.28K	﹤0.01%	3299
2023 Q1	$1.35K	Buy	+33	New	+$1.31K	﹤0.01%	2887
2022 Q4	–	Sell	-2	Closed	–	–	3479
2022 Q3	$0	Sell	2 -1	-33%	-$56	﹤0.01%	3403
2022 Q2	$0	Buy	+3	New	+$197	﹤0.01%	3261

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Parallel Advisors's PCRX Position: Q2 2026 in Review

Parallel Advisors held its Pacira BioSciences (PCRX) position steady in Q2 2026 at 178 shares worth $4.52K. The position accounts for ﹤0.01% of the portfolio, ranked #3254.

Parallel Advisors first reported a position in PCRX in Q2 2022 and has held it in 15 quarters since. The position peaked at $9.45K in Q4 2023. 254 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

Parallel Advisors held 178 shares of Pacira BioSciences worth $4.52K as of Q2 2026.
Parallel Advisors left its Pacira BioSciences share count unchanged in Q2 2026.
Pacira BioSciences made up ﹤0.01% of Parallel Advisors's portfolio in Q2 2026, its #3254 holding.
Parallel Advisors first reported a position in Pacira BioSciences in Q2 2022 and has held it in 15 quarters since.
Parallel Advisors's Pacira BioSciences position peaked at $9.45K in Q4 2023.
254 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.